Statistically significant improvement in primary endpoint of proportion of patients with three point or greater reduction in mean worst itching intensity NRS score vs. placebo (p=0.02)...

AGM will take place as planned on 14 May, 2020 under extraordinary conditions Shareholders are not allowed to attend in person and are requested to vote via independent proxy St Gallen, 31 March...

Net sales and EBITDA exceeded raised full-year guidance as a result of continued execution of the three strategic growth drivers Etienne Jornod to step down as Executive Chairman. Jacques...

St Gallen, 3 March 2020 - Vifor Pharma today announced that Fitch Ratings (Fitch) has initiated coverage of Vifor Pharma with an investment grade BBB- credit rating and a stable outlook. This...

Partnership brings together Vifor Pharma’s world-class iron deficiency portfolio with Fresenius Kabi’s market-leading patient access in China Gives Vifor Pharma access to largest iron...

St Gallen, 17 February 2020 – Vifor Pharma today announced that it has agreed to purchase a US Food and Drug Administration (FDA) priority review voucher (PRV). A PRV entitles the holder to...

For a fifth consecutive year, Iron Deficiency Day aims to inform about the impact and symptoms of iron deficiency Iron Deficiency Day 2019 encourages people to ‘take iron seriously’ Supported...

Achieved both primary endpoints of clinical remission at weeks 26 and 52 with statistical superiority of avacopan over standard of care at 52 weeks Significantly reduced glucocorticoid toxicity...

St Gallen, 18 November 2019 – Vifor Pharma today announced the appointment of Lee Heeson as President International and member of the Executive Committee as of February 1st, 2020. Lee Heeson...

St Gallen, 11 September 2019 – Vifor Pharma today announced changes to its management. Dr Klaus Henning Jensen will join the company as Chief Medical Officer and Member of the Executive...